Canopy Growth Corp is making headlines with a notable surge in its stock price, driven by impressive growth in its medical marijuana sales.
In the latest trading session, Canopy Growth Corp (WEED.TO) saw its stock price soar by 7.58%, closing at CA$1.42. This increase follows strong performance in its medical marijuana segment, which has been a bright spot for the company amid mixed results in other areas.
Investor takeaway: While Canopy Growth's medical marijuana sales are showing promising growth, investors should remain cautious about the overall health of the company's other business segments.
Advertisement
Canopy Growth Corp
WEED.TO
WEED.TO
Canopy Growth Corp
WealthAwesomeAdvertisement
Market cap
$623.30M
52W high
$3.28
52W low
$1.18
1W change
+9.23%
Beta
2.41
Analyst Price Targets
Based on analyst covering WEED
Wall Street analysts forecast WEED stock price to rise 42.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.02
+42.3% Upside
Current Price
C$1.42
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on WEED's historical volatility
30-Day Vol
39.7%
Annualized
90-Day Vol
60.7%
Annualized
Trend (90d)
-17.4%
Annualized drift
90d Mean
C$1.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.39 | C$1.21 – C$1.60 |
| 60 trading days | C$1.36 | C$1.12 – C$1.65 |
| 90 trading days | C$1.33 | C$1.05 – C$1.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Canopy Growth's Medical Marijuana Sales Soar by 27%
The company's medical marijuana segment has outperformed expectations, significantly contributing to its recent stock price increase.
Bull case
The 27% increase in medical marijuana revenue for the fourth quarter shows strong demand and hints at a possible turnaround for Canopy Growth. The acquisition of MTL Cannabis could further enhance its market position, making it an attractive option for investors seeking growth in the cannabis sector.
Bear case
Despite the positive news, Canopy Growth's recreational marijuana segment struggled, with only a 1% revenue increase in the fourth quarter. Additionally, the company's ongoing negative earnings and declining gross margins raise concerns about its long-term viability.
Strong Growth in Medical Marijuana Sales
Advertisement
Canopy Growth's recent report highlighted a remarkable 27% increase in medical marijuana revenues for the fourth quarter of fiscal 2026. This growth is a positive indicator for the company, especially as it continues to strengthen its position in the Canadian medical marijuana market through strategic acquisitions like MTL Cannabis. Investors may find this segment a beacon of hope amidst the company's broader challenges.
Mixed Results in Other Segments
While the medical marijuana division is thriving, Canopy Growth's recreational cannabis business only saw a 1% revenue increase in the fourth quarter. This raises concerns about the sustainability of growth in this area. Additionally, the company's international cannabis sales experienced a year-over-year decline despite a quarterly increase, indicating potential supply chain issues that could affect future performance.
What Lies Ahead for Canopy Growth
Investors should approach Canopy Growth with caution. The recent stock surge is encouraging, but the company has not reported positive earnings since going public over a decade ago. With ongoing challenges in several business segments and a recapitalized balance sheet, it may take more than just one successful division to restore investor confidence in Canopy Growth. For those interested in the cannabis sector, it might be wise to monitor developments closely before making any investment decisions.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
